FDA Finalizes Its Mandatory Cosmetics Recall Guidance

FDA has finalized its guidance on mandatory cosmetics recalls — the agency's first attempt at spelling out how it will use the forced-recall power Congress gave it in 2022 but FDA has not yet had occasion to invoke. Trade press reported the finalization on 22 October 2026; it replaces a draft FDA issued 18 December 2025 with, reporters say, no substantive changes.

A power that didn't exist before 2022

Unlike drugs, devices and most foods, cosmetics historically sat outside FDA's mandatory-recall authority entirely. The agency could ask a company to pull a product; it could not order one to. MoCRA changed that, alongside a broader set of new cosmetics powers — facility registration, product listing, safety-substantiation recordkeeping, adverse-event reporting — that took effect through 2024 and 2025. Section 611 is the enforcement backstop to that modernization: the authority to compel a recall when a company won't act on its own. This guidance operationalizes only that one piece, nearly three years after the statute creating it was signed.

The two-part finding FDA must make

The statute sets a conjunctive test, not an either-or: FDA needs a reasonable probability that the cosmetic is adulterated or misbranded, and, separately, a reasonable probability that using it will cause serious adverse health consequences or death. A product that is merely mislabeled, without that second finding of serious health risk, does not clear the bar for a mandatory order. And even clearing both prongs does not let FDA skip straight to compulsion: the agency must first give the responsible person — typically the manufacturer or distributor — an opportunity to recall voluntarily. Only if that offer is declined, and only with the FDA Commissioner's own sign-off, can a mandatory order issue. Concentrating that authority in the Commissioner, rather than delegating it further down, is itself a check on how often the power gets used.

Due process: the informal hearing

A company that receives a mandatory recall order is not without recourse. Section 611 entitles the recipient to an informal hearing under 21 CFR Part 16 — the general regulatory hearing procedure FDA uses across its programs — held no less than 10 days after the order issues. That window gives a recipient a short but real opportunity to contest the agency's factual basis before the recall runs its course, a due-process feature built into the statute itself rather than left to agency discretion.

What stayed the same, and what it means for compliance teams

Reporting on the final guidance describes no substantive changes from the December 2025 draft after FDA reviewed public comments — so companies that already mapped their recall-readiness plans against the draft do not need to redo that work. The document itself is nonbinding: it describes FDA's current thinking on how Section 611 will be applied, and does not itself create new legal obligations beyond what the statute already requires. The practical takeaway for cosmetics regulatory and quality teams is less about the guidance's text and more about what it confirms is now a live possibility: a recall FDA can compel, not merely request, if a voluntary one doesn't happen first.

Frequently asked questions

What did FDA finalize?

Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry (Docket FDA-2025-D-2246), which explains how FDA will use its mandatory cosmetics-recall authority under Section 611 of the FD&C Act, added by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Trade press reported the finalization on 22 October 2026; it replaces a draft FDA issued 18 December 2025, reportedly with no substantive changes.

When can FDA order a mandatory recall?

Only after finding a reasonable probability that a cosmetic is adulterated or misbranded, and a reasonable probability that its use will cause serious adverse health consequences or death. FDA must first give the responsible person an opportunity to recall voluntarily, and only the FDA Commissioner can issue or vacate a mandatory recall order.

What happens after an order issues?

The recipient is entitled to an informal hearing under 21 CFR Part 16, held no less than 10 days after the order issues, where they can contest the basis for the recall.

Does the guidance create new legal obligations?

No. It is nonbinding guidance describing FDA's current thinking on how it will apply authority that already exists in the statute. The legal obligations come from Section 611 itself, not from the guidance document.